IRD Key Statistics, Chart & Performance
The current stock price of IRD is 2.7 USD. In the past month the price increased by 35.68%. In the past year, price increased by 143.24%.
IRD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IRD. When comparing the yearly performance of all stocks, IRD is one of the better performing stocks in the market, outperforming 95.52% of all stocks.
IRD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IRD. IRD may be in some trouble as it scores bad on both profitability and health.
IRD Financial Highlights
Over the last trailing twelve months IRD reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS increased by 23.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -188.81% | ||
| ROE | -1143% | ||
| Debt/Equity | 0.18 |
IRD Forecast & Estimates
14 analysts have analysed IRD and the average price target is 7.96 USD. This implies a price increase of 194.67% is expected in the next year compared to the current price of 2.7.
For the next year, analysts expect an EPS growth of 37.05% and a revenue growth 48.43% for IRD
IRD Ownership
About IRD
Company Profile
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 18 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Company Info
OPUS GENETICS INC
8 Davis Drive, Suite 220
Durham NORTH CAROLINA US
Employees: 18
Phone: 12486819815
OPUS GENETICS INC / IRD FAQ
Can you describe the business of OPUS GENETICS INC?
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 18 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Can you provide the latest stock price for OPUS GENETICS INC?
The current stock price of IRD is 2.7 USD. The price decreased by -4.59% in the last trading session.
Does OPUS GENETICS INC pay dividends?
IRD does not pay a dividend.
What is the ChartMill rating of OPUS GENETICS INC stock?
IRD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about OPUS GENETICS INC (IRD) stock?
14 analysts have analysed IRD and the average price target is 7.96 USD. This implies a price increase of 194.67% is expected in the next year compared to the current price of 2.7.
Can you provide the number of employees for OPUS GENETICS INC?
OPUS GENETICS INC (IRD) currently has 18 employees.
What is the Short Interest ratio of OPUS GENETICS INC (IRD) stock?
The outstanding short interest for OPUS GENETICS INC (IRD) is 1.43% of its float.